Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Leases: 2019-2024

Historic Capital Leases for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $2.2 million.

  • Kymera Therapeutics' Capital Leases rose 3.44% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 3.44%. This contributed to the annual value of $2.2 million for FY2024, which is 71.10% up from last year.
  • According to the latest figures from FY2024, Kymera Therapeutics' Capital Leases is $2.2 million, which was up 71.10% from $1.3 million recorded in FY2023.
  • Kymera Therapeutics' Capital Leases' 5-year high stood at $2.2 million during FY2024, with a 5-year trough of $604,000 in FY2020.
  • Moreover, its 3-year median value for Capital Leases was $1.3 million (2023), whereas its average is $1.6 million.
  • Per our database at Business Quant, Kymera Therapeutics' Capital Leases crashed by 48.15% in 2020 and then soared by 88.74% in 2021.
  • Over the past 5 years, Kymera Therapeutics' Capital Leases (Yearly) stood at $604,000 in 2020, then soared by 88.74% to $1.1 million in 2021, then grew by 9.30% to $1.2 million in 2022, then rose by 4.41% to $1.3 million in 2023, then soared by 71.10% to $2.2 million in 2024.